Developer docs
API playgroundTry for free, no card

Search company profiles

IHAS

Full company profile

uuid02lmiop

Namestring
IHAS
Legal namestring
iHAS Ltd (ИХАС ЕООД)
Websiteurl
ihas.eu
Company typeenum
Private
Founded yearstring
-
Descriptiontext

iHAS is a privately-held Bulgarian healthcare services company founded in 2012 and headquartered in Sofia (15a Krum Kyulyavkov Str., 1172 Sofia). It operates a dual-line business: (1) exclusive Bulgarian distribution of the Oncotype DX genomic diagnostic test portfolio under representation agreements with Genomic Health Inc. and Exact Sciences Inc., and (2) facilitation of outbound medical tourism for Bulgarian patients to Switzerland's Hirslanden Hospital Group. The company serves Bulgarian cancer patients — primarily newly diagnosed with breast, colon, or prostate cancer — and the prescribing oncologists, surgeons, and medical geneticists who use test results to inform chemotherapy and recurrence-risk decisions. Secondary customers include Bulgarian patients seeking second opinions or treatment abroad through iHAS-organized consultations, hospital admissions, and travel logistics.

The core product distributed is Oncotype DX — a multi-gene expression assay platform that analyzes tumor tissue (21 genes for breast cancer, 12 for colon cancer, plus prostate and DCIS variants) and outputs a Recurrence Score (0–100) predicting ten-year recurrence risk and the likelihood of chemotherapy benefit. iHAS does not own or develop this technology; it operates as the order-and-results intermediary for Bulgaria. The medical-tourism offering layers remote document review, second-opinion consultations with international experts, hospital placement at Hirslanden's 14 Swiss facilities (concentrated in Zurich and Bern), airport transfers, accommodation, translation, and cultural programming. A web-based patient registry and social network is offered as an adjunct service.

iHAS generates revenue through two streams: one-time per-test fees on Oncotype DX orders (pricing is quote-based and not covered by Bulgaria's National Health Insurance Fund, requiring patient or institutional out-of-pocket payment) and professional-service fees for medical-tourism facilitation. The go-to-market is sales-led and direct, relying on physician referrals, the company's website, and inbound phone/email contact rather than digital marketing infrastructure. The company has no disclosed funding rounds, no headcount data, and no institutional ownership signals; it appears founder-controlled with a single named founder (George Pishtiyski) and a clinical consultant (Dr. Ivanka Dimova).

Short descriptiontext

iHAS is a Bulgarian healthcare services company that distributes Oncotype DX genomic cancer diagnostic tests in Bulgaria as the exclusive representative of Genomic Health and Exact Sciences, and facilitates medical tourism to Switzerland's Hirslanden Hospital Group for Bulgarian patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSofia, Bulgaria
HQ citystring
Sofia
HQ countrystring
Bulgaria
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
genomic diagnostic tests, medical tourism services, cancer diagnostics distribution, personalized oncology treatment, healthcare facilitation services
Industry4 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAFAMAJ
Reference & Esoteric Testing Laboratories
NAICS code3 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Cancer Diagnostics & Medical Tourism Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Genetic Analysis Assays
TypeOne Time License
Description

Sale of Oncotype DX diagnostic tests for breast, colon, and prostate cancer. These are one-time tests performed on tumor tissue samples to provide genomic information for treatment decisions.

ihas.eu
2Medical Tourism Services
TypeProfessional Services
Description

Facilitation services for Bulgarian patients seeking medical treatment abroad, including organizing remote and face-to-face consultations with international experts, arranging treatment at Hirslanden hospitals in Switzerland, providing airport transfers, accommodation, translation services, and cultural programs.

ihas.eu
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Pricing details1 tier
1Oncotype DX breast cancer test for invasive cancer
ModelOtherBilling cadenceOne time/ perpetual license
Notes

Test performed on tissue from initial surgery. Patient or physician orders through iHAS Ltd, official representative of Genomic Health Inc. and Exact Sciences Inc. for Bulgaria. Not covered by NHIF.

ihas.eu
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

IHAS distributes Oncotype DX genomic diagnostic tests for breast, colon, prostate, and DCIS cancer in Bulgaria as the exclusive local representative of Genomic Health Inc. and Exact Sciences Inc., enabling personalized cancer treatment decisions through multi-gene tumor analysis. The company additionally provides medical tourism facilitation services connecting Bulgarian patients with international healthcare providers, notably the Hirslanden hospital group in Switzerland.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 37% of patients had their treatment decision changed based on Recurrence Score results
+2 more records
Product overview1 text field

iHAS is a Bulgarian healthcare services company offering a portfolio of genomic diagnostic tests and medical tourism services. The core products are Oncotype DX tests (for breast cancer, colon cancer, prostate cancer, and DCIS) distributed in Bulgaria in partnership with Genomic Health Inc. and Exact Sciences Inc. These genomic assays analyze tumor tissue to provide personalized recurrence risk scores and treatment recommendations. Additionally, iHAS provides medical tourism services facilitating access to Swiss hospitals (Hirslanden Group) and international medical experts. The company also offers a web-based patient registry/social network for patients with specific conditions.

Product and service4 records
1Oncotype DX Breast Cancer Assay
CategoryCancer diagnostics
Description

Genomic diagnostic test for early-stage, estrogen receptor-positive (ER+) breast cancer that analyzes 21 genes in tumor tissue to provide a Recurrence Score (0-100), predicting 10-year recurrence risk and likelihood of chemotherapy benefit for patients.

2Oncotype DX Colon Cancer Assay
CategoryCancer diagnostics
Description

First commercial genomic diagnostic test evaluating expression levels of 12 genes in tumor samples to assess recurrence risk in Stage II colon cancer patients, supporting individualized treatment decisions.

3Oncotype DX Prostate Cancer Assay
CategoryCancer diagnostics
Description

Genomic test developed to help men with newly diagnosed, early-stage prostate cancer select appropriate treatment by determining cancer risk before treatment begins, using a proprietary analysis platform for formalin-fixed paraffin-embedded prostate tissue.

4Oncotype DX DCIS Test
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

iHAS Ltd is the exclusive representative of Genomic Health Inc. and Exact Sciences Inc. for Bulgaria. Genomic Health is a global medical company (NASDAQ: GHDX) that provides actionable genomic information to personalize treatment decisions. Their Oncotype DX tests for breast, colon, and prostate cancer are clinically validated and included in major international treatment guidelines.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

iHAS works with Hirslanden hospital group, one of Switzerland's leading private hospital groups with 14 first-class hospitals. The partnership focuses on clinics in Zurich (Klinik Hirslanden, Klinik im Park) and Bern (Klinik Beau-Site, Klinik Permanence, Salem Hospital). iHAS acts as a connecting link between foreign patients and Swiss hospitals, guaranteeing optimal and fast solutions for medical problems.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

iHAS Ltd is the exclusive representative of Exact Sciences Inc. for Bulgaria alongside Genomic Health Inc. Exact Sciences develops and provides diagnostic tests for cancer treatment decisions.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Europe's largest medical diagnostics services provider, offering routine and esoteric/molecular testing including oncology across the continent. Relevant incumbent peer because it competes for the same Bulgarian and CEE physician demand for advanced oncology diagnostics that iHAS distributes.

TypeDirect peer
Description

Medical tourism facilitator that arranges treatment abroad (notably in Germany, Switzerland and Israel) for patients from Eastern Europe and the CIS. Closely comparable to iHAS' Hirslanden medical tourism line in target customer (CEE patients seeking Western European care) and service scope.

TypeBroad incumbent
Description

Global diagnostics provider with extensive European laboratory operations offering specialty and molecular testing. Comparable to iHAS as a broad incumbent that ultimately delivers many of the same advanced oncology assays iHAS helps distribute in Bulgaria.

TypeEmerging player
Description

Global platform that connects patients with international clinics and facilitates cross-border medical travel. Comparable to iHAS' medical tourism arm in bundling provider selection, logistics and treatment coordination for outbound patients.

TypeBroad incumbent
Description

Owner of the Oncotype DX franchise that iHAS exclusively distributes in Bulgaria. Comparable as the upstream developer of the core product iHAS sells and as the principal whose strategic decisions (pricing, exclusivity, direct entry) materially affect iHAS' economics.

TypeDirect peer
Description

Sweden-based healthcare group operating diagnostics, specialty care and hospitals across Central and Eastern Europe including Bulgaria. Most directly comparable peer to iHAS because it combines clinical laboratory/diagnostic services with broader healthcare delivery in the same CEE geography iHAS serves.

TypeRegional player
Description

Austrian private hospital group with a dedicated international patient office catering to CEE and CIS patients seeking advanced Western European care. Comparable to iHAS' medical tourism model in geography and patient origin.

8Docrates Cancer Center
TypeRegional player
Description

Privately owned Finnish specialty cancer hospital serving international patients from across Europe and Russia. Comparable to the Hirslanden-side of iHAS' offering as a destination for personalized cancer diagnostics and treatment for cross-border patients.

TypeRegional player
Description

Swiss private hospital network competing with Hirslanden for international and CEE medical tourism patients. Comparable as an alternative Swiss destination that Bulgarian patients could be channeled to, similar to how iHAS works with Hirslanden today.

TypeBroad incumbent
Description

European clinical laboratory and diagnostics network with strong presence in molecular and specialty testing. Comparable to iHAS in that it provides the underlying molecular diagnostic infrastructure (including oncology testing) that iHAS effectively distributes in Bulgaria.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IHAS

Cancer Diagnostics & Medical Tourism Servicesihas.eu

iHAS is a Bulgarian healthcare services company that distributes Oncotype DX genomic cancer diagnostic tests in Bulgaria as the exclusive representative of Genomic Health and Exact Sciences, and facilitates medical tourism to Switzerland's Hirslanden Hospital Group for Bulgarian patients.

What IHAS does

iHAS is a privately-held Bulgarian healthcare services company founded in 2012 and headquartered in Sofia (15a Krum Kyulyavkov Str., 1172 Sofia). It operates a dual-line business: (1) exclusive Bulgarian distribution of the Oncotype DX genomic diagnostic test portfolio under representation agreements with Genomic Health Inc. and Exact Sciences Inc., and (2) facilitation of outbound medical tourism for Bulgarian patients to Switzerland's Hirslanden Hospital Group. The company serves Bulgarian cancer patients — primarily newly diagnosed with breast, colon, or prostate cancer — and the prescribing oncologists, surgeons, and medical geneticists who use test results to inform chemotherapy and recurrence-risk decisions. Secondary customers include Bulgarian patients seeking second opinions or treatment abroad through iHAS-organized consultations, hospital admissions, and travel logistics.

The core product distributed is Oncotype DX — a multi-gene expression assay platform that analyzes tumor tissue (21 genes for breast cancer, 12 for colon cancer, plus prostate and DCIS variants) and outputs a Recurrence Score (0–100) predicting ten-year recurrence risk and the likelihood of chemotherapy benefit. iHAS does not own or develop this technology; it operates as the order-and-results intermediary for Bulgaria. The medical-tourism offering layers remote document review, second-opinion consultations with international experts, hospital placement at Hirslanden's 14 Swiss facilities (concentrated in Zurich and Bern), airport transfers, accommodation, translation, and cultural programming. A web-based patient registry and social network is offered as an adjunct service.

iHAS generates revenue through two streams: one-time per-test fees on Oncotype DX orders (pricing is quote-based and not covered by Bulgaria's National Health Insurance Fund, requiring patient or institutional out-of-pocket payment) and professional-service fees for medical-tourism facilitation. The go-to-market is sales-led and direct, relying on physician referrals, the company's website, and inbound phone/email contact rather than digital marketing infrastructure. The company has no disclosed funding rounds, no headcount data, and no institutional ownership signals; it appears founder-controlled with a single named founder (George Pishtiyski) and a clinical consultant (Dr. Ivanka Dimova).

IHAS firmographics

Firmographics
Name
IHAS
Legal name
iHAS Ltd (ИХАС ЕООД)
Website
https://ihas.eu
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Short description
iHAS is a Bulgarian healthcare services company that distributes Oncotype DX genomic cancer diagnostic tests in Bulgaria as the exclusive representative of Genomic Health and Exact Sciences, and facilitates medical tourism to Switzerland's Hirslanden Hospital Group for Bulgarian patients.
Ownership category
akta.pro rank

IHAS industry classification

Industry
Product category
Cancer Diagnostics & Medical Tourism Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
SECONDARYHLAFAMAJ
Reference & Esoteric Testing Laboratories

Keywords

  • Genomic diagnostic tests
  • Medical tourism services
  • Cancer diagnostics distribution
  • Personalized oncology treatment
  • Healthcare facilitation services

Where IHAS is headquartered

Location

Headquarters

HQ city
Sofia
HQ country
Bulgaria
HQ region
Europe

Offices1 record

Markets served

IHAS business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Genetic Analysis Assays: Sale of Oncotype DX diagnostic tests for breast, colon, and prostate cancer. These are one-time tests performed on tumor tissue samples to provide genomic information for treatment decisions.
  2. Medical Tourism Services: Facilitation services for Bulgarian patients seeking medical treatment abroad, including organizing remote and face-to-face consultations with international experts, arranging treatment at Hirslanden hospitals in Switzerland, providing airport transfers, accommodation, translation services, and cultural programs.

Pricing tiers

ModelBillingPrice
OtherOne time/ perpetual licenseOncotype DX breast cancer test for invasive cancer

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

IHAS product offering

Product offering

Core offering

IHAS distributes Oncotype DX genomic diagnostic tests for breast, colon, prostate, and DCIS cancer in Bulgaria as the exclusive local representative of Genomic Health Inc. and Exact Sciences Inc., enabling personalized cancer treatment decisions through multi-gene tumor analysis. The company additionally provides medical tourism facilitation services connecting Bulgarian patients with international healthcare providers, notably the Hirslanden hospital group in Switzerland.

Product overview

iHAS is a Bulgarian healthcare services company offering a portfolio of genomic diagnostic tests and medical tourism services. The core products are Oncotype DX tests (for breast cancer, colon cancer, prostate cancer, and DCIS) distributed in Bulgaria in partnership with Genomic Health Inc. and Exact Sciences Inc. These genomic assays analyze tumor tissue to provide personalized recurrence risk scores and treatment recommendations. Additionally, iHAS provides medical tourism services facilitating access to Swiss hospitals (Hirslanden Group) and international medical experts. The company also offers a web-based patient registry/social network for patients with specific conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oncotype DX Breast Cancer Assay Genomic diagnostic test for early-stage, estrogen receptor-positive (ER+) breast cancer that analyzes 21 genes in tumor tissue to provide a Recurrence Score (0-100), predicting 10-year recurrence risk and likelihood of chemotherapy benefit for patients.
  • Oncotype DX Colon Cancer Assay First commercial genomic diagnostic test evaluating expression levels of 12 genes in tumor samples to assess recurrence risk in Stage II colon cancer patients, supporting individualized treatment decisions.
  • Oncotype DX Prostate Cancer Assay Genomic test developed to help men with newly diagnosed, early-stage prostate cancer select appropriate treatment by determining cancer risk before treatment begins, using a proprietary analysis platform for formalin-fixed paraffin-embedded prostate tissue.
  • Oncotype DX DCIS Test

Quantifiable outcome

  • 37% of patients had their treatment decision changed based on Recurrence Score results
  • +2 more outcomes

Companies that use IHAS

Customer profile

Segments3 records

Ideal customer profiles2 records

IHAS technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

IHAS partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Genomic Health, Inc.coreChannel Partner/ Reseller/ DistributoriHAS Ltd is the exclusive representative of Genomic Health Inc. and Exact Sciences Inc. for Bulgaria. Genomic Health is a global medical company (NASDAQ: GHDX) that provides actionable genomic information to personalize treatment decisions. Their Oncotype DX tests for breast, colon, and prostate cancer are clinically validated and included in major international treatment guidelines.
  • Hirslanden Hospital GroupcoreStrategic or Co-development PartneriHAS works with Hirslanden hospital group, one of Switzerland's leading private hospital groups with 14 first-class hospitals. The partnership focuses on clinics in Zurich (Klinik Hirslanden, Klinik im Park) and Bern (Klinik Beau-Site, Klinik Permanence, Salem Hospital). iHAS acts as a connecting link between foreign patients and Swiss hospitals, guaranteeing optimal and fast solutions for medical problems.
  • Exact Sciences Inc.coreChannel Partner/ Reseller/ DistributoriHAS Ltd is the exclusive representative of Exact Sciences Inc. for Bulgaria alongside Genomic Health Inc. Exact Sciences develops and provides diagnostic tests for cancer treatment decisions.

Scale indicators4 records

Recent moves5 records

Expansion highlights3 records

IHAS competitors and assessment

Company assessment

Broad incumbents

  • SYNLAB: Europe's largest medical diagnostics services provider, offering routine and esoteric/molecular testing including oncology across the continent. Relevant incumbent peer because it competes for the same Bulgarian and CEE physician demand for advanced oncology diagnostics that iHAS distributes.
  • Sonic Healthcare: Global diagnostics provider with extensive European laboratory operations offering specialty and molecular testing. Comparable to iHAS as a broad incumbent that ultimately delivers many of the same advanced oncology assays iHAS helps distribute in Bulgaria.
  • Exact Sciences: Owner of the Oncotype DX franchise that iHAS exclusively distributes in Bulgaria. Comparable as the upstream developer of the core product iHAS sells and as the principal whose strategic decisions (pricing, exclusivity, direct entry) materially affect iHAS' economics.
  • Unilabs: European clinical laboratory and diagnostics network with strong presence in molecular and specialty testing. Comparable to iHAS in that it provides the underlying molecular diagnostic infrastructure (including oncology testing) that iHAS effectively distributes in Bulgaria.

Direct peers

  • Booking Health: Medical tourism facilitator that arranges treatment abroad (notably in Germany, Switzerland and Israel) for patients from Eastern Europe and the CIS. Closely comparable to iHAS' Hirslanden medical tourism line in target customer (CEE patients seeking Western European care) and service scope.
  • Medicover: Sweden-based healthcare group operating diagnostics, specialty care and hospitals across Central and Eastern Europe including Bulgaria. Most directly comparable peer to iHAS because it combines clinical laboratory/diagnostic services with broader healthcare delivery in the same CEE geography iHAS serves.

Emerging players

  • Medigo: Global platform that connects patients with international clinics and facilitates cross-border medical travel. Comparable to iHAS' medical tourism arm in bundling provider selection, logistics and treatment coordination for outbound patients.

Regional players

  • Wiener Privatklinik: Austrian private hospital group with a dedicated international patient office catering to CEE and CIS patients seeking advanced Western European care. Comparable to iHAS' medical tourism model in geography and patient origin.
  • Docrates Cancer Center: Privately owned Finnish specialty cancer hospital serving international patients from across Europe and Russia. Comparable to the Hirslanden-side of iHAS' offering as a destination for personalized cancer diagnostics and treatment for cross-border patients.
  • Genolier Swiss Medical Network: Swiss private hospital network competing with Hirslanden for international and CEE medical tourism patients. Comparable as an alternative Swiss destination that Bulgarian patients could be channeled to, similar to how iHAS works with Hirslanden today.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

IHAS social profiles

Digital presence

IHAS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IHAS leadership team

Management profile

Number of profiles

Profiles2 records

IHAS funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IHAS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IHAS

What does IHAS do?

IHAS distributes Oncotype DX genomic diagnostic tests for breast, colon, prostate, and DCIS cancer in Bulgaria as the exclusive local representative of Genomic Health Inc. and Exact Sciences Inc., enabling personalized cancer treatment decisions through multi-gene tumor analysis. The company additionally provides medical tourism facilitation services connecting Bulgarian patients with international healthcare providers, notably the Hirslanden hospital group in Switzerland.

Is IHAS a public or private company?

IHAS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was IHAS founded?

IHAS was founded in -1. It employs 1 to 10 people.

Where is IHAS based?

IHAS is headquartered in Sofia, Bulgaria, in the Europe region.

How does IHAS make money?

Two revenue lines are on record. Genetic Analysis Assays are the primary driver. The others are medical Tourism Services.

Who are IHAS's main competitors?

Broad incumbents on record are SYNLAB, Sonic Healthcare, Exact Sciences and Unilabs. Direct peers are Booking Health and Medicover. Medigo is listed as an emerging player. Regional players are Wiener Privatklinik, Docrates Cancer Center and Genolier Swiss Medical Network.

Does IHAS have an API?

No public API is recorded for IHAS.

What industry is IHAS in?

IHAS's product category is Cancer Diagnostics & Medical Tourism Services. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales